Merck Aktie

66,80 EUR +0,40 EUR +0,60 %

10:21:56

FSE

76,15 USD -0,66 USD -0,86 %

nachbörslich12:10:00

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.167,57 Mrd. EUR

KGV14,77Div. Rendite3,14%

WKNA0YD8Q

ISINUS58933Y1055

SymbolMRK

Merck Aktien News

Sortieren:Datum Meistgelesen

22.04.25PR NewswireHealth Canada Approves KEYTRUDA® Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients with Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)

14.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

13.04.25PR NewswireMRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit

WerbungMerck-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

08.04.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

01.04.25PR NewswireClass Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors - Contact Levi & Korsinsky

31.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

28.03.25PR NewswireMRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit

25.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

25.03.25PR NewswireMRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

21.03.25PR NewswireLevi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRK

19.03.25PR NewswireHealth Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as ...

17.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

13.03.25PR NewswireMerck & Co., Inc. Class Action: The Gross Law Firm Reminds Merck Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025 - MRK

07.03.25PR NewswireMerck & Co., Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MRK

03.03.25PR NewswireMRK Purchasers Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit

03.03.25PR NewswireINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines - MRK

03.03.25PR NewswireMRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm

28.02.25PR NewswireMRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

25.02.25PR NewswireClass Action Filed Against Merck & Co., Inc. (MRK) - April 14, 2025 Deadline to Join - Contact Levi & Korsinsky

16.02.25PR NewswireMRK INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Merck & Co., Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

11.02.25PR NewswireHealth Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination w...

04.02.25PR NewswireCIBC introduces additional Canadian Depositary Receipts ("CDRs")

08.11.24PR NewswireCanada's Drug Agency Recommends WINREVAIR® (sotatercept) for Reimbursement

05.09.24PR NewswireMerck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WELIREG® (belzutifan)

04.09.24PR NewswireWINREVAIR® (sotatercept) is now authorized for use in Canada for Adults with Pulmonary Arterial Hypertension

22.08.24PR NewswireHealth Canada Approves KEYTRUDA® for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer (mUC) with no prior systemic therapy for mUC, in combination...

09.07.24PR NewswireElanco Completes Sale of Aqua Business

08.07.24PR NewswireASNA and Athinia® collaborate to boost semiconductor manufacturing yields through improved data sharing and traceability of subcomponent parts

09.05.24PR NewswireHealth Canada Approves KEYTRUDA® for adult patients with locally advanced unresectable or metastatic biliary tract carcinoma, in combination with gemcitabine-based chemotherapy

19.04.24PR NewswireHealth Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcino...

15.03.24PR NewswireFarmSee Ltd Announces the Completion of a Minority Investment in its Swine Monitoring Platform

12.02.24PR NewswireHealth Canada Approves KEYTRUDA® in combination with trastuzumab and chemotherapy, as a first-line treatment for patients with locally advanced unresectable or metastatic HER2-positive gastric or ...

Merck News

Merck News: auf dieser Seite finden Sie alle Merck News und Nachrichten zur Merck Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Merck News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Merck News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.